Welcome to our dedicated page for Aimei Health Technology Co. SEC filings (Ticker: afjku), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Aimei Health Technology Co.'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Aimei Health Technology Co.'s regulatory disclosures and financial reporting.
Aimei Health Technology Co., Ltd deposited $150,000 into its trust account to extend the deadline to complete its initial business combination by one month, moving the termination date from September 6, 2025 to October 6, 2025. This is the tenth of up to 12 one‑month extensions allowed under its current Articles of Association.
To fund this extension, the company issued a $150,000 unsecured promissory note on September 5, 2025 to its sponsor, Aimei Health Ltd, and United Hydrogen Group Inc., with each contributing $75,000. The note bears no interest and becomes due when the company completes a business combination with United Hydrogen. The payees may instead convert the note into private units at $10.00 per unit, each unit consisting of one ordinary share and one right to receive one‑fifth of one ordinary share, immediately before the business combination closes.
Aimei Health Technology Co., Ltd. completed a $69.0 million initial public offering of 6,900,000 Units and a $3.32 million private placement, placing $73,784,549 in a U.S. trust account invested in short-term Treasuries or qualifying money market funds until a business combination closes or funds are distributed to redeeming public shareholders. As of December 31, 2024, the company held $28,208 of cash outside the trust, reported a working capital deficit of $747,377 and a shareholders' deficit presentation reflecting 6,900,000 shares subject to redemption at $10.10 per share. The registrant recorded $31.27 million of redemptions of 2,904,267 shares and made multiple $150,000–$227,700 monthly extension deposits into the trust to extend the combination period. The filing discloses the company has not adopted a formal cybersecurity risk management program and notes reliance on third-party technologies and limited resources to investigate or remediate cyber vulnerabilities.
Aimei Health Technology Co., Ltd is a blank check company formed to complete an initial business combination and has not commenced operations. The company holds the majority of its proceeds in a trust for public shareholders, reporting $2,138 in cash, $44,511,399 in its Trust Account and total assets of $44,556,037. Ordinary shares subject to possible redemption totaled 3,995,733 at a redemption value of $11.14, and total shareholders' deficit was $(2,859,328).
For the six months ended June 30, 2025 the company reported net income of $609,632, driven by interest on trust assets of $1,064,650 offset by formation and operating costs of $455,018. The company amended and extended its combination period multiple times (now extended to September 6, 2025), issued extension promissory notes totaling $1,205,400 as of June 30, 2025, and redeemed 2,904,267 shares for approximately $31.27 million. Management disclosed substantial doubt about the company’s ability to continue as a going concern if it fails to complete a business combination within the prescribed period.
Mizuho Financial Group reports beneficial ownership of 550,600 common shares of Aimei Health Technology, representing 9.0% of the outstanding class. The filing states Mizuho has sole voting and dispositive power over these shares and that the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
The filing is made by the parent holding company and discloses that related entities (Mizuho Bank, Mizuho Americas LLC) may be deemed indirect beneficial owners through a wholly owned broker-dealer subsidiary.
W. R. Berkley Corporation and its subsidiary Berkley Insurance Company report beneficial ownership of 425,361 ordinary shares of Aimei Health Technology Co., Ltd (ordinary shares, $0.0001 par). That stake represents 6.9% of the company’s outstanding shares based on the issuer’s publicly reported total of 6,121,733 shares. The filing shows shared voting and shared dispositive power over the 425,361 shares rather than sole control.
The statement notes the securities are held in the ordinary course of business and were not acquired to change or influence control of the issuer. Reporting persons are organized in Delaware and list a Greenwich, CT address for their principal business office.
FAQ
What is the current stock price of Aimei Health Technology Co. (afjku)?
